Institutional shares held 62.7 Million
36.9K calls
476K puts
Total value of holdings $44.5M
$26K calls
$337K puts
Market Cap $88.1M
124,072,000 Shares Out.
Institutional ownership 50.51%
# of Institutions 100


Latest Institutional Activity in MCRB

Top Purchases

Q1 2024
Hudson Bay Capital Management LP Shares Held: 5.43M ($3.85M)
Q1 2024
Woodline Partners LP Shares Held: 2.05M ($1.45M)
Q1 2024
Vanguard Group Inc Shares Held: 6.73M ($4.78M)
Q1 2024
Goldman Sachs Group Inc Shares Held: 1.06M ($756K)
Q1 2024
D. E. Shaw & Co., Inc. Shares Held: 486K ($345K)

Top Sells

Q1 2024
Millennium Management LLC Shares Held: 1.03M ($730K)
Q1 2024
Tang Capital Management LLC Shares Held: 907K ($644K)
Q1 2024
Susquehanna International Group, LLP Shares Held: 635K ($451K)
Q1 2024
Bank Of America Corp Shares Held: 1.65M ($1.18M)
Q1 2024
Black Rock Inc. Shares Held: 6.83M ($4.85M)

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at MCRB

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
233K Shares
From 8 Insiders
Exercise of conversion of derivative security 233K shares
Sell / Disposition
78.1K Shares
From 8 Insiders
Open market or private sale 78.1K shares

Track Institutional and Insider Activities on MCRB

Follow Seres Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MCRB shares.

Notify only if

Insider Trading

Get notified when an Seres Therapeutics, Inc. insider buys or sells MCRB shares.

Notify only if

News

Receive news related to Seres Therapeutics, Inc.

Track Activities on MCRB